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INTRODUCTION
Rare diseases (RD) are a disparate group of disorders that can 
affect any body system. Most RD have a genetic association and 
are often severely debilitating; they impair physical and mental 
abilities and shorten life expectancy. As such, RD pose a chal-
lenge for the families living with these conditions and the medi-
cal community.1
It has been argued that RD should be recognized as a public 
health priority.2,3 It is commonly quoted that, combined, RD affect 
6–8% of the population; however, there are limited data support-
ing this figure.4 Furthermore, the true burden of RD is difficult to 
estimate. This has resulted in a lack of recognition of the impor-
tance of RD for health-care planning and resource allocation.5 To 
date, only a few population-level studies of the impact of RD have 
been published. One such recent study of a population-based 
registry in Italy found that RD are responsible for nearly twice as 
many years of life lost in the population as diabetes.6
Epidemiological information regarding RD is challenging 
to collect for a number of reasons. Several thousands of RD 
are described, but the exact figure is impossible to establish 
because it depends directly on what is defined as an RD. Several 
definitions of RD are in use around the world, usually with a 
threshold of rarity based on either a prevalence or a maximum 
number of patients in a region.7–9
One cost-effective approach to collecting information 
regarding RD would be to use longitudinal population or health 
administrative data sets.6,10,11 However, routine data-collection 
systems are not without limitations for identifying people with 
RD. The most significant issue concerns the coding and clas-
sification of RD.5 The International Classification of Diseases 
(ICD) provides specific coding for only a limited number 
(approximately 5.1%) of RD.5 In the 10th revision of the ICD, 
one code may be shared by multiple rare and non-RD, or a 
single disease may require a specific combination of codes to 
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Purpose: It has been argued that rare diseases should be recognized 
as a public health priority. However, there is a shortage of epidemio-
logical data describing the true burden of rare diseases. This study 
investigated hospital service use to provide a better understanding of 
the collective health and economic impacts of rare diseases.
Methods: Novel methodology was developed using a carefully 
 constructed set of diagnostic codes, a selection of rare disease cohorts 
from hospital administrative data, and advanced data- linkage tech-
nologies. Outcomes included health-service use and hospital admis-
sion costs.
Results: In 2010, cohort members who were alive represented 
approximately 2.0% of the Western Australian population. The 
cohort accounted for 4.6% of people discharged from hospital and 
9.9% of hospital discharges, and it had a greater average length of stay 
than the general population. The total cost of hospital discharges for 
the cohort represented 10.5% of 2010 state inpatient hospital costs.
Conclusions: This population-based cohort study provides strong 
new evidence of a marked disparity between the proportion of the 
population with rare diseases and their combined health-system 
costs. The methodology will inform future rare-disease studies, and 
the evidence will guide government strategies for managing the ser-
vice needs of people living with rare diseases.
Genet Med advance online publication 22 September 2016
Key Words: cost; data linkage; epidemiology; hospitalizations; rare 
disease
1Office of Population Health Genomics, Public Health Division, Department of Health, Government of Western Australia, Perth, Australia; 2Data Linkage Branch, Purchasing and 
System Performance, Department of Health, Government of Western Australia, Perth, Australia; 3Epidemiology Branch, Public Health Division, Department of Health, Government 
of Western Australia, Perth, Australia; 4Centre for Population Health Research, Curtin University, Perth, Australia; 5INSERM, US14, Paris, France; 6Faculty of Education, University 
of Western Australia, Perth, Australia; 7Telethon Kids Institute, Perth, Australia; 8Genetic Services WA, King Edward Memorial Hospital, Perth, Australia; 9School of Paediatrics 
and Child Health, University of Western Australia, Perth, Australia; 10Western Australian Register of Developmental Anomalies, King Edward Memorial Hospital, Perth, Australia; 
11Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia; 12School of Pathology and Laboratory Medicine, University of Western Australia, 
Perth, Australia; 13Centre for Comparative Genomics, Murdoch University, Perth, Australia; 14Public Health Division, Department of Health, Government of Western Australia, 
Perth, Australia. Correspondence: Caroline E. Walker (caroline.walker@health.wa.gov.au)
The collective impact of rare diseases in Western Australia: 
an estimate using a population-based cohort
Caroline E. Walker, BSc(Hons), PhD1, Trinity Mahede, BSc(Hons), MPH1, Geoff Davis, BA(Hons), PGDipPH2,  
Laura J. Miller, MA, PhD3, Jennifer Girschik, PhD3, Kate Brameld, BSc(Hons), PhD4,  
Wenxing Sun, BHlthSc, GDipBiostats3, Ana Rath, MD5, Ségolène Aymé, MD, PhD5,  
Stephen R. Zubrick, MSc, PhD6,7, Gareth S. Baynam, FRACP, PhD1,7–11, Caron Molster, BBus(Hons)1, 




WALKER et al  |  Impact of rare diseases in Western AustraliaOriginal research article
be accurately identified. Furthermore, there are issues regard-
ing physician knowledge and use of appropriate codes for cer-
tain RD.5,12 These issues affect the accuracy and comprehensive 
recording of RD and hamper data ascertainment.
To address this issue, the international consortium Orphanet 
has developed a comprehensive classification and coding sys-
tem for RD called Orpha codes.13 Orpha codes identify clini-
cally unique and distinct entities with prevalence equal to no 
more than 1 in 2,000 in the general European population. The 
advantages of the system have been recognized to the extent 
that they now form the basis for the classification of RD in the 
next release of the ICD (ICD-11).13 However, the use of Orpha 
codes is limited by the fact that most routine data-collection 
systems do not use these codes as a classification tool. Orphanet 
has cross-referenced Orpha codes to ICD-10, which has helped 
to address this limitation, but use of the Orphanet classifica-
tion with systems using ICD-10 is still limited. In Australia, 
beginning 1 July 1999, routine data-collection systems have 
been using an Australian modification of ICD-10 called ICD-
10-AM, which has not been cross-referenced to Orpha codes.
In Western Australia (WA), the Department of Health main-
tains numerous administrative data collections from services 
such as hospitals, health services, and practitioners. These rou-
tine data sets, in combination with data-linkage infrastructure,14 
mean that WA has a unique capacity to identify and follow up 
with people living with RD and to address some of the gaps in 
epidemiological data regarding the collective impact of RD.
The aim of the WA RD study was to develop a resource set 
based on Orpha codes that could be used to investigate RD in 
WA. The resource set was used to interrogate the WA Hospital 
Morbidity Data Collection (HMDC) to identify a cohort of peo-
ple in order to investigate (i) the types of RD reported, (ii) the 
numbers of patients with RD in WA, (iii) utilization of particular 
health services, and (iv) the cost of RD to the WA health sys-
tem. This paper provides an overview of the study methodology, 
describes cohort demographics, and provides the first snapshot 
of health-service utilization of a cohort of people with RD.
MATERIALS AND METHODS
RD resource set
As a result of the limitations of using Orpha codes in the 
Australian context, it was necessary to undertake work to first 
match Orpha/ICD-10 codes to ICD-10-AM codes and validate 
the matching process. We have named the outcome of this work 
the RD resource set.
Because the cohort for the study was to be selected from the 
WA HMDC,15 we used information from this data collection to 
assist with the creation of the RD resource set. When develop-
ing the resource set, an RD was defined as any noninfectious 
disease with a prevalence of less than 1 in 2,000 in the general 
WA population.
We started with 585 RD Orpha codes identified by Orphanet 
and specifically mapped to one or a set of ICD-10 codes. 
With guidance from clinical coders, these ICD-10 codes were 
matched to their equivalent ICD-10-AM codes. A process of 
“back translation” to Orpha codes was then undertaken to 
ensure that the ICD-10-AM codes described the same diseases 
as those captured by the Orpha codes. In some cases, because 
of discrepancies between the ICD-10 and ICD-10-AM coding 
systems, the ICD-10-AM code(s) that specifically corresponded 
to an Orpha code was different from the ICD-10 code provided 
by Orphanet. Decisions regarding how to assign ICD-10-AM 
codes for these diseases were made in conjunction with WA 
medical coding experts.
Each Orpha code was classified into a disease category or 
medical specialty. Orphanet classifies entities following a prin-
ciple of polyhierarchy; a disorder is assigned to all categories 
corresponding to the medical specialties to which it is relevant. 
However, to avoid multiple counting during data analysis, a set 
of formalized rules provided by Orphanet16 was used to linear-
ize the classifications such that each Orpha code was assigned 
to one of the 22 Orphanet classifications.
We then undertook the process of reviewing the RD resource 
set in keeping with the definition of an RD used in this study. 
First, a total of 96 Orpha codes that were assigned to the infec-
tious-disease classification were removed from the resource 
set. Second, to overcome potential differences between the 
European and WA populations, we estimated the period preva-
lence for each RD in the resource set during the study period. 
For these prevalence calculations, data regarding the number 
of people who were discharged from hospital for each RD from 
1 July 1999 to 31 December 2010 were extracted from HMDC 
and divided by the WA population size at the midpoint of the 
period (March 2005). For diseases with a period prevalence 
higher than 1 in 2,000, clinical guidance was sought regard-
ing whether each disease should be included in the resource 
set used for cohort selection. A total of 22 diseases were deter-
mined to be not rare in WA and were therefore removed from 
the resource set.
The final RD resource set contained 467 Orpha codes and 
their assigned Orphanet classification, cross-referenced to 
1,084 ICD-10-AM codes. The resource set is provided in the 
Supplementary Materials and Methods online.
Study population and data sources
This retrospective cohort study included all individuals who 
had an HMDC record with one of the 1,084 ICD-10-AM codes 
from the RD resource set recorded in any diagnosis field and 
a discharge date between 1 July 1999 and 31 December 2010.
All inpatient hospital records for each member of the cohort 
for the same time period were also extracted. Variables extracted 
included, but were not limited to, month and year of birth, sex, 
all diagnosis fields, admission and discharge dates, and postal 
code. The Western Australian Registry of Births, Deaths, and 
Marriages was used to identify those in the cohort who had 
died during the study period.
These data were linked via probabilistic linkage using com-
mon identifiers, including name, address, and birth date.14 
Multiple linkage passes were conducted to minimize both false-
positive and false-negative errors, followed by a clerical review 
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to resolve doubtful links. The procedures used for the extrac-
tion of data from the WA Data Linkage System have been inter-
nationally accepted as best practice.15
Data analysis
To facilitate international comparisons, RD were analyzed by 
Orpha codes. Statistics describing the frequency and character-
istics of patients, discharges, and RD diagnostic categories were 
calculated for the entire 11.5-year study period. Descriptive sta-
tistics for length of stay and costs of discharges were calculated. 
Because of the skewed nature of length-of-stay data, both mean 
and medians are presented.
The age for each patient was calculated on either 31 December 
2010 or date of death, whichever was earlier. The following age 
groups were used: younger than 1 year, 1–4 years, and then 
subsequent 10-year age groups until >85 years. Geographical 
location was categorized as either metropolitan or “rural and 
remote” and was determined by a person’s last known postal 
code of residence.
Hospital-discharge information is presented for all discharges 
and for the subgroup of discharges that had RD codes recorded 
in any diagnosis field (RD-related hospital discharges). This 
was done to capture the full picture of inpatient hospitalization 
activity for people with RD, in light of the well-documented 
issues with accurate coding of RD (see Introduction). Hospital 
discharges for the cohort were examined for the entire study 
period (1 July 1999 to 31 December 2010). Additionally, a 
“2010 cohort” was assembled from a 1-year data set of people 
discharged between 1 January 2010 and 31 December 2010. 
Compilation of this 2010 cohort enabled population data com-
parisons to all discharges in WA during that year and facilitated 
cost calculations.
Costs in Australian dollars (AUD) were calculated by 
applying average cost weights17,18 to the Australian Refined 
Diagnosis-Related Group (AR-DRG) for each discharge during 
2010 (each hospital discharge is assigned an AR-DRG, a clas-
sification system used to group patients with similar clinical 
characteristics requiring comparable hospital services). Using 
these costs, the total cost of all hospital discharges and the total 
cost of all RD-related hospital discharges for 2010 were cal-
culated. These costs were compared with those of all hospital 
 discharges in WA during the same year. Analysis for this study 
was conducted using SAS version 9.3 (SAS Institute, Cary, NC).
Ethics
The study was approved by the Human Research Ethics 
Committee of the WA Department of Health (approval 2012/74).
RESULTS
Whole cohort description
The whole cohort consisted of 61,279 people discharged from a 
hospital in WA with at least one RD recorded in the diagnosis 
fields of their hospital record during the period 1 July 1999 to 31 
December 2010. There were slightly more males (52.5%) than 
females (47.5%) in the whole cohort, and the mean and median 
ages were 50.5 years (SD, 27.4) and 55 years, respectively. The 
majority (99%) had a WA residential postal code recorded. Of 
the patients with a recorded WA residential postal code, 78.4% 
resided in the metropolitan area and 21.6% resided in rural and 
remote areas. This mirrors the geographical distribution of the 
WA general population.19
Approximately 94% (441) of the 467 Orpha codes in the 
RD resource set were identified in the whole cohort during 
the study period. The majority of the cohort (87.1%) had only 
one RD code recorded anywhere in their HMDC records; the 
remaining 12.9% had 2–12 RD codes recorded. The most com-
mon Orphanet classification was rare developmental defects 
during embryogenesis (19.1%), followed by rare neoplastic 
disease (14.5%) and rare neurological diseases (12.4%). Table 1 
displays the demographic profile of those in each Orphanet 
classification. The table shows that a person identified as hav-
ing more than one RD code could be assigned more than one 
Orphanet classification. However, if a person had more than 
one RD code in an Orphanet classification, they were counted 
only once in that classification.
A total of 16,066 deaths were recorded among cohort mem-
bers over the study period; 45,213 members were alive (73.8%) 
as of 31 December 2010. The WA population for the same time 
point was 2,294,411.20 Consequently, in December 2010 the 
whole cohort represented 2.0% of the WA population. The age 
and gender distributions of members alive as of 31 December 
2010 are displayed in Figure 1.
The whole cohort: hospital inpatient service use
The 61,279 cohort members accounted for a total of 912,492 
hospital discharges, of which just over one-quarter (26.5%, 
n = 242,099) were RD-related (i.e., had at least one RD code in 
a diagnosis field for that discharge) during the 11.5-year study 
period. The mean length of stay for all cohort discharges was 
3.8 days; for the subset of RD-related discharges, it was 5.5 days.
The 2010 cohort: hospital inpatient service use and costs
Approximately one-third (20,946) of the patients in the whole 
cohort were discharged from hospital during 2010, account-
ing for 88,515 discharges (“2010 cohort” in Table 2). The 
2010 cohort represented 4.6% of the total number of patients 
 discharged form hospital and 9.9% of all discharges in WA dur-
ing that period. The mean number of discharges per patient 
during 2010 for the 2010 cohort was twice that of all people 
discharged from hospital in WA. For RD-related discharges 
only, the mean number of discharges per patient was only 
slightly more than that of all people discharged from hospital 
in WA. The mean length of stay for all discharges during 2010 
for the 2010 cohort was 3.6 days; for the subset of RD-related 
discharges, it was 5.5 days. For comparison, the mean length of 
stay for all hospital discharges in WA in 2010 was 2.9 days.
Rare neoplastic diseases contributed the most to the num-
ber of RD-related discharges for the 2010 cohort during 2010 
(Table 3). There were almost four times as many discharges 
coded with rare neoplastic diseases than the three next highest 
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classifications (rare hematologic, rare developmental defect 
during embryogenesis, and rare neurologic diseases).
The longest mean length of stay for RD-related discharges for 
the 2010 cohort was recorded for rare endocrine diseases (33.5 
days), although the median length of stay for this classification 
was substantially shorter (1 day). Rare respiratory, hepatic, neu-
rologic, and cardiac diseases and rare developmental defects 
 during embryogenesis were the only classifications with a 
median length of stay longer than 1 day.
By applying the cost weights to the AR-DRGs, the total cost of 
all hospital discharges and the total cost of all RD-related  hospital 
discharges for the 2010 cohort were calculated. The total cost 
associated with hospital discharges for the 2010 cohort during 
2010 was AUD 394,947,610, which was 10.5% of the total WA 
inpatient hospital expenditure (AUD 3,759,339,298) (Table 2). 
Analysis of the subset of RD-related hospital discharges in 2010 
showed that the cost was AUD 173,322,256, which was 4.6% of 
the total WA inpatient hospital expenditure. Interestingly, the cost 
per discharge for RD-related discharges was approximately AUD 
3,000 higher than the cost per discharge for all WA discharges.
DISCUSSION
This study identified a group of RD patients from an adminis-
trative data set and extracted valuable linked information about 
their health-service usage. The figures reported here provide 
striking new evidence of the collective impact of RD on the 
state’s health system and the patients it serves. Our findings of 
a marked disparity between the proportion of the population 
with an RD and their combined cost to the inpatient hospital 
system will raise awareness among medical professionals and 
broader health departments regarding RD. Moreover, the study 
methodology is generalizable to other populations and could 
support further international epidemiological studies of the 
collective impact of RD.
The whole cohort in this study represents approximately 
2.0% of the state population in 2010; however, they had a 
higher mean number of hospital discharges, a longer mean 
length of stay than the general population, and account for 
between 4.6 and 10.5% of state inpatient hospital costs for 
that year. This disparity not only contributes to the imme-
diate cost of hospital care but also will have consequential 
Table 1 Demographic characteristic of members of the whole cohort by Orphanet classification in decreasing order of 
frequency
Orphanet classification Number of people (%) Mean age Median age % Male % Metropolitan area
Rare developmental defect during embryogenesis 12,766 (19.1%) 26.7 16 50.8% 77.1%
Rare neoplastic disease 9,655 (14.5%) 62.2 66 56.9% 80.3%
Rare neurologic disease 8,255 (12.4%) 60.0 65 51.8% 79.9%
Rare respiratory disease 4,656 (7.0%) 48.1 61 52.0% 79.5%
Rare cardiac disease 4,536 (6.8%) 61.7 65 71.3% 77.0%
Rare systemic or rheumatologic disease 3,941 (5.9%) 47.7 51 44.6% 74.4%
Rare hematologic disease 3,896 (5.8%) 54.7 60 52.7% 82.3%
Rare inborn errors of metabolism 3,144 (4.7%) 56.6 59 62.0% 74.2%
Rare skin disease 2,469 (3.7%) 57.2 59 40.8% 74.2%
Rare otorhinolaryngologic disease 2,306 (3.5%) 48.3 57 44.4% 77.5%
Rare gastroenterologic disease 2,209 (3.3%) 66.6 73 73.7% 81.2%
Rare endocrine disease 1,624 (2.4%) 42.4 45 42.1% 77.0%
Rare eye disease 1,618 (2.4%) 26.9 14 51.7% 77.6%
Rare bone disease 1,406 (2.1%) 29.9 24 60.4% 73.7%
Rare hepatic disease 1,101 (1.6%) 58.6 61 40.0% 81.6%
Rare urogenital disease 915 (1.4%) 56.4 61 23.9% 80.3%
Rare gynecologic or obstetric disease 764 (1.1%) 45.3 43 0.0% 80.7%
Rare odontologic disease 727 (1.1%) 34.3 26 45.3% 84.9%
Rare renal disease 531 (0.8%) 34.7 34 61.0% 77.2%
Rare immune disease 150 (0.2%) 41.0 37.5 50.7% 82.1%
Rare circulatory system disease 69 (0.1%) 56.0 61 17.4% 88.2%
Rare abdominal surgical disease 10 (0.0%) 46.4 48.5 20.0% 90.0%
Total 66,748 50.5 55 52.6 78.4%
Individuals who had more than one rare disease recorded in their hospital discharge records could be counted in more than one classification.
Figure 1  Age and gender distribution of the whole cohort on 31 
December 2010. The demographic distribution of members of the whole 
cohort who were alive on 31 December 2010 (n = 45,213). This group 
represents approximately 2.0% of the WA population during 2010.
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social and economic implications for patients, carers, and 
family members. For reasons outlined here, our study cohort 
is probably an underestimate of the number of people with 
an RD, and the total cost of inpatient hospital service use by 
this group would be noticeably greater than that reported 
here. Furthermore, with the inclusion of outpatient, general 
practitioner, mental health, emergency, and allied health- 
service costs, the total health-system cost attributed to RD is 
expected to be substantially greater.
Data from this study can be broadly extrapolated to dem-
onstrate the potential implications of RD for the whole of 
Australian inpatient hospital discharges. In 2010, the WA 
population was approximately 10.2% of Australia’s population 
(22,477,000). Using the cost of hospital discharges for the 2010 
cohort, estimated as between AUD 173 million (RD-related) 
and 395 million (all discharges), inpatient hospital discharges 
for a cohort selected from the whole of Australia could be esti-
mated as being in the range of AUD 1.7 billion -AUD 3.9 bil-
lion per year. Using 2010 average monetary exchange rates, this 
would equate to USD 1.8 to 4.1 billion and EUR 1.4 to 3.1 bil-
lion for the year.21
Although numerous studies have determined the costs of 
specific RD in particular settings, there is limited population-
based evidence of the collective economic burden of RD. These 
data support other studies that have shown that genetic dis-
eases result in higher rates of hospitalizations, longer lengths of 
stay, and greater economic burden than for patients without a 
genetic disease.22,23 Reports of the impact of genetic diseases on 
different types of hospital utilization such as emergency depart-
ment presentations, intensive care units, and general hospital 
Table 2 Numbers of people and discharges, LOS and costs for 2010 cohort members and the WA general population 
during 2010
People (% of total 
persons discharged)









Mean cost  
per discharge
Cost, AUD  
(% of total cost)
2010  
Cohort
All discharges 20,946 (4.6%) 88,515 (9.9%) 4.2 3.6 1.0 $4,461.93 $395 million (10.5%)
Rare disease–
related discharges
8,880 (2.0%) 24,057 (2.7%) 2.7 5.5 1.0 $7,204.65 $173 million (4.6%)
Total WA discharges 448,260 894 010 2.0 2.9 1.0 $4,205.03 $3,759 million
AUD, Australian dollars; LOS, length of stay; WA, Western Australia.
Table 3 Numbers of RD-related discharges and patients discharged from hospital for an RD-related discharge and LOS of  
RD-related discharges for 2010 cohort members by Orphanet classification in decreasing order of frequency
Orphanet classification Number of discharges Number of people Mean LOS (days) Median LOS (days)
Rare neoplastic disease 9,786 1,788 3.4 1
Rare hematologic disease 2,613 671 2.3 1
Rare developmental defect during embryogenesis 2,237 1,629 11.1 2
Rare neurologic disease 2,075 1,103 10.4 3
Rare inborn errors of metabolism 1,599 495 2.7 1
Rare systemic or rheumatologic disease 1,474 612 8.5 1
Rare respiratory disease 893 525 17.6 5
Rare cardiac disease 729 566 7.3 3
Rare immune disease 482 51 1.1 1
Rare gastroenterologic disease 447 315 3.6 1
Rare skin disease 370 281 7.9 1
Rare otorhinolaryngologic disease 331 267 11.3 1
Rare endocrine disease 312 160 33.6 1
Rare bone disease 275 209 3.7 1
Rare eye disease 237 189 29.4 1
Rare hepatic disease 200 151 10.7 5
Rare renal disease 186 80 6.9 1
Rare urogenital disease 158 88 2.1 1
Rare gynecologic or obstetric disease 94 92 1.5 1
Rare odontologic disease 89 88 1.5 1
Rare circulatory system disease 8 7 1.3 1
Rare abdominal surgical disease a a a a
Hospital discharges could be counted in more than one Orphanet classification if more than one RD code was recorded in the diagnosis fields.
LOS, length of stay; RD, rare disease.
aBecause fewer than five people were discharged from hospital for a rare abdominal surgical disease, no data are presented for this classification.
Genetics in medicine
6
WALKER et al  |  Impact of rare diseases in Western AustraliaOriginal research article
wards indicate that the proportion of admissions due to genetic 
diseases ranges from 2 to 11%.22–26
The disease classification with the highest number of peo-
ple discharged from hospital throughout the whole study 
period was rare developmental defects during embryogenesis 
(Table 1). Interpretation of this result must take into consid-
eration that nearly one-third of the RD codes used to select 
the whole cohort were in this category. Diseases classified as 
rare developmental defects during embryogenesis include 
chromosomal defects that are complex and severely debilitat-
ing and that would contribute to high use of hospital services, 
particularly pediatric services. Linking data in this study to 
data from the WA Register of Developmental Anomalies 
could enable further investigation of the use of pediatric hos-
pital services by young people living with specific RD.
The disease category of rare neoplastic diseases had the 
second highest number of people discharged from hospital 
during the study period. Rare neoplastic diseases mirror the 
challenges that rare conditions collectively present in clinical 
practice. Notably, these include a lack of knowledge and experi-
ence among practitioners and pathologists27 leading to late or 
incorrect diagnosis, difficulties accessing clinical expertise, and 
appropriate referral pathways and treatments.28–32
The whole cohort of this study represents 2.0% of the state pop-
ulation in 2010. This is comparable to a study by Mazzucato et al. 
that extrapolated prevalence data calculated from a population-
based registry to estimate that 1.3 to 2% of the European Union 
population are living with an RD.6 However, this is consider-
ably lower than the usually reported estimates of 6–8% of the 
population living with an RD.2,33 Results from this study should 
be considered as minimum values for reasons that include the 
following: (i) the RD resource set used in this study contained 
only 467 of the estimated 6,000 to 8,000 RD, (ii) RD are likely to 
be incorrectly or insufficiently coded in administrative data sets 
because physicians may not know or use appropriate codes for 
certain RD,12 and (iii) people who used outpatient, general prac-
titioner, emergency, and allied health services without inpatient 
services were not included. Although it is difficult to estimate 
the extent, these factors could contribute to a significant under-
estimate of the number of people in WA with an RD.
Substantial elements of the shortfalls of RD coding inter-
nationally will be addressed through the next release of ICD 
codes (ICD-11).5 Specifically, Orphanet coding is expected 
to be formally integrated within ICD-11. This means there 
will be an internationally accepted and comprehensive data-
classification system that supports RD if and when ICD-11 is 
adopted and implemented. Health-data systems may consider 
earlier incorporation of Orpha codes into data collections so 
that as ICD-11 is introduced into health-data collections, there 
will be the capacity to continue to effectively record and report 
local RD data. Such actions are consistent with the European 
Commission Expert Group on RD recommendation adopted 
in November 2014 for national health-care coding systems to 
consider using Orpha codes in addition to ICD-10 codes when 
an RD has no specific ICD-10 code.5,34
Several definitions of RD are in use around the world, and many 
of these refer to both the prevalence and severity of burden—in 
particular, that RD are life-threatening or chronically debilitat-
ing.35 Other studies have also reported that determining whether 
a disease was rare or common was difficult.36 The study reported 
here developed and implemented an RD resource set that was 
designed to complement the coding used in the specific data col-
lections in WA. Although tailored, this approach may be general-
izable to other health systems and populations. The RD resource 
set used a definition of RD based exclusively on a prevalence of 
less than 1 in 2,000 people. As a result, the list includes a mixture 
of both acute and chronic diseases with varying degrees of sever-
ity. Furthermore, we were unable to determine when the cohort 
members were first diagnosed with an RD and whether the con-
dition is lifelong or resolves following treatment. The study makes 
the assumption that when a person is hospitalized for an RD, they 
continue to be afflicted with that disease during the study period. 
Additionally, because of inconsistencies in the way RD codes are 
coded in hospital records, we were unable to definitively deter-
mine which discharges for the cohort were directly related to their 
RD and which were not. To address this, we examined summary 
data for all discharges for the cohort as well as the subset of dis-
charges for which an RD code is recorded in a diagnosis field.
This study used linked health data to provide a mechanism to 
explore the hospital service use of people living with RD. Using 
a data-linkage infrastructure meant that our study could identify 
people living with RD and examine their inpatient hospital  service 
use over more than a decade across a statewide health system. 
Although the methodology has some acknowledged limitations, 
the findings make an important contribution to the understand-
ing of the collective impact of RD. We have addressed some of the 
gaps in epidemiological data regarding the collective impact of 
RD for which evidence is currently limited. This study highlights 
the marked disparity between the proportion of the population 
with an RD and their combined cost to the state health system. 
Along with recent findings that suggest that not all health-care 
needs of people living with RD are being met,37 these data further 
support the need for improved access to early diagnosis and care 
coordination for patients with RD. Recognizing RD as a public 
health priority, the data presented here have been instrumental 
in guiding clinical service delivery of the Rare and Undiagnosed 
Diseases Diagnostic Service.38 Furthermore, this evidence has 
informed policymakers in the development of public health strat-
egies, such as the WA Rare Diseases Strategic Framework.39
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
ACKNOWLEDGMENTS
The authors acknowledge invaluable contributions from the follow-
ing: Deborah Yagmich, principal coding trainer, WA Department of 
Health, for providing mapping assistance between Orpha codes and 
ICD-10-AM codes and expert operational coding knowledge; Data 
Linkage Branch staff, for assisting in the linked data application, data 
Genetics in medicine
7
Impact of rare diseases in Western Australia  |  WALKER et al Original research article
extraction, and linkage; and staff at the HMDC and the Registrar 
General (Registry of Birth, Deaths, and Marriages), for providing 
the data. G.S.B. acknowledges the Raine Clinician Research Fellow-
ship. K.B. is funded through Lotterywest Data Linkage Infrastructure 
Funding. This study was approved by the Human Research Ethics 
Committee of the WA Department of Health (approval 2012/74).
DISCLOSURE
The authors declare no conflict of interest.
REFERENCES
 1. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important 
medical and social issue. Lancet 2008;371:2039–2041.
 2. European Organisation for Rare Diseases. Rare Diseases: Understanding This 
Public Health Priority. Eurordis: Paris, France, 2005. http://www.eurordis.org/
IMG/pdf/princeps_document-EN.pdf. Accessed 7 October 2015.
 3. Valdez R, Ouyang L, Bolen J. Public Health and Rare Diseases: Oxymoron No 
More. Prev Chronic Dis 2016;13:E05.
 4. Groft SC, Posada de la Paz M. Rare diseases—avoiding misconceptions and 
establishing realities: the need for reliable epidemiological data. In: Groft SC, 
Posada de la Paz M (eds). Rare Diseases Epidemiology Springer: Dordrecht, The 
Netherlands, 2010:3–14.
 5. Aymé S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible 
in health information systems through appropriate coding. Orphanet J Rare Dis 
2015;10:35.
 6. Mazzucato M, Visonà Dalla Pozza L, Manea S, Minichiello C, Facchin P. A 
population-based registry as a source of health indicators for rare diseases: the 
ten-year experience of the Veneto Region’s rare diseases registry. Orphanet J 
Rare Dis 2014;9:37–48.
 7. Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet 
2008;372:889–890.
 8. The European Parliament and the Council of the European Union. Regulation (EC) 
no. 141/2000 of the European Parliament and of the Council of 16 December 
1999 on Orphan Medicinal Products. 1999. http://ec.europa.eu/health/files/
eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf. Accessed 21 March 2016.
 9. 107th Congress of the United States of America. Rare Diseases Act of 2002. 
HR. 4013. 2002. http://history.nih.gov/research/downloads/PL107-280.pdf. 
Accessed 21 March 2016.
 10. Ward  MM. Estimating rare disease prevalence from administrative 
hospitalization databases. Epidemiology 2005;16:270–271.
 11. Grosse SD, Boulet SL, Grant AM, Hulihan MM, Faughnan ME. The use of US 
health insurance data for surveillance of rare disorders: hereditary hemorrhagic 
telangiectasia. Genet Med 2014;16:33–39.
 12. Stargardt T, Schreyögg J. A framework to evaluate the effects of small area 
variations in healthcare infrastructure on diagnostics and patient outcomes of 
rare diseases based on administrative data. Health Policy 2012;105:110–118.
 13. Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S. Representation of 
rare diseases in health information systems: the Orphanet approach to serve a 
wide range of end users. Hum Mutat 2012;33:803–808.
 14. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health 
records in Western Australia: development of a health services research linked 
database. Aust N Z J Public Health 1999;23:453–459.
 15. Holman CD, Bass AJ, Rosman DL, et al. A decade of data linkage in Western 
Australia: strategic design, applications and benefits of the WA data linkage 
system. Aust Health Rev 2008;32:766–777.
 16. Orphanet. Linearization rules for Orphanet classifications. Orphanet procedural 
document. Reports collection. Orphanet: Paris, France, 2014. http://www.
orpha.net/orphacom/cahiers/docs/GB/Orphanet_linearisation_rules.pdf. 
Accessed 7 October 2015.
 17. Australian Institute of Health and Welfare Australian refined diagnosis-related 
groups (AR-DRG) data cubes 2015. http://www.aihw.gov.au/hospitals-data/
ar-drg-data-cubes/. Accessed 1 April 2015.
 18. Australian Government Department of Health. Round 14 (2009–10) 
National Public Cost Weight Tables - version 6.0x and version 5.2. Australian 
Government: Canberra, Australia, 2012. http://www.health.gov.au/internet/
main/publishing.nsf/Content/Round_14-cost-reports. Accessed 1 April 2015.
 19. Australian Bureau of Statistics. Western Australia, 3235.0—Population by Age 
and Sex, Regions of Australia, 2010. 2012. http://www.abs.gov.au/ausstats/
abs@.nsf/Products/3235.0~2010~Main+Features~Western+Australia?OpenD
ocument. Accessed 12 October 2015.
 20. Australian Bureau of Statistics. Table 55. Estimated Resident Population by Single 
Year of Age, Western Australia. Australian Government: Canberra, Australia, 
2011. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%20
2010?OpenDocument. Accessed 12 October 2015.
 21. Reserve Bank of Australia. Historical data—Exchange rates—Daily—2010 to 
2013. Reserve Bank of Australia: Sydney, Australia, 2015. http://www.rba.gov.
au/statistics/historical-data.html. Accessed 29 December 2015.
 22. Dye DE, Brameld KJ, Maxwell S, et al. The impact of single gene and 
chromosomal disorders on hospital admissions of children and adolescents: a 
population-based study. Public Health Genomics 2011;14:153–161.
 23. Dye DE, Brameld KJ, Maxwell S, Goldblatt J, O’Leary P. The impact of single 
gene and chromosomal disorders on hospital admissions in an adult population. 
J Community Genet 2011;2:81–90.
 24. McCandless SE, Brunger JW, Cassidy SB. The burden of genetic disease on 
inpatient care in a children’s hospital. Am J Hum Genet 2004;74:121–127.
 25. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. 
Contribution of birth defects and genetic diseases to pediatric hospitalizations. 
A population-based study. Arch Pediatr Adolesc Med 1997;151:1096–1103.
 26. FitzPatrick DR, Skeoch CH, Tolmie  JL. Genetic aspects of admissions 
to a paediatric intensive care unit. Arch Dis Child 1991;66:639–641.
 27. Gatta G, Capocaccia R, Trama A, Martínez-García C, RARECARE working group. 
The Burden of Rare Cancers in Europe. In: Posada de la Paz M, Groft SC, (eds). Rare 
Diseases Epidemiology. Springer: Dordrecht, The Netherlands, 2010:285–303.
 28. Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare 
cancer burden in Europe. Eur J Cancer 2011;47:2493–2511.
 29. Knight AW, Senior TP. The common problem of rare disease in general practice. 
Med J Aust 2006;185:82–83.
 30. Le Cam Y. Patients’ Needs and Expectations Concerning Access to Health 
Services—The Eurordiscare 3 study. 4th European Conference on Rare Diseases: 
“Patients at the Heart of Rare Disease Policy Development,” Lisbon, Portugal, 
27–28 November 2007.
 31. Phillips WR. Zebras on the commons: rare conditions in family practice. J Am 
Board Fam Pract 2004;17:283–286.
 32. Zurynski YA, Reeve KN, Elliott EJ. International conferences on rare diseases: 
initiatives in commitment, patient care and connections. Med J Aust 
2007;187:597.
 33. Aymé S, Rodwell C. 2013 Report on the State of the Art of Rare Disease 
Activities in Europe. Scientific Secretariat of the European Union Committee of 
Experts on Rare Diseases: Paris, France, 2013. http://www.eucerd.eu/upload/
file/Reports/2013ReportStateofArtRDActivities.pdf. Accessed 10 August 2015.
 34. European Commission Expert Group on Rare Diseases. Recommendation on 
Ways to Improve Codification for Rare Diseases in Health Information Systems. 
European Commission Expert Group on Rare Diseases: Luxembourg, 2014. 
http://ec.europa.eu/health/rare_diseases/docs/recommendation_coding_
cegrd_en.pdf. Accessed 10 August 2015.
 35. Dawkins HJ, Molster CM, Youngs LM, O’Leary PC. Awakening Australia to Rare 
Diseases: symposium report and preliminary outcomes. Orphanet J Rare Dis 
2011;6:57.
 36. Yoon PW, Chen B, Faucett A, et al. Public health impact of genetic tests at the 
end of the 20th century. Genet Med 2001;3:405–410.
 37. Molster C, Urwin D, Di Pietro L, et al. Survey of healthcare experiences of 
Australian adults living with rare diseases. Orphanet J Rare Dis 2016;11:30.
 38. Baynam G, Pachter N, McKenzie F, et al. The rare and undiagnosed diseases 
diagnostic service - application of massively parallel sequencing in a state-wide 
clinical service. Orphanet J Rare Dis 2016;11:77.
 39. Department of Health Western Australia. WA Rare Diseases Strategic 
Framework 2015–2018. Department of Health Western Australia: Perth, 
Australia, 2015.
This work is licensed under a Creative Commons 
Attribution 4.0 International License. The 
images or other third party material in this article are 
included in the article’s Creative Commons license, unless 
indicated otherwise in the credit line; if the material is 
not included under the Creative Commons license, users 
will need to obtain permission from the license holder to 
reproduce the material. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/
© The Author(s) (2016)
Genetics in medicine
